暂无内容
暂无数据
Seres Therapeutics, Inc.2025财年实现净利润5.70百万美元,同比增加104.52%
市场透视03/14 03:00
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
道琼斯03/14 02:33 · 评级/大行评级
Seres Therapeutics Price Target Maintained With a $22.00/Share by Canaccord Genuity
Seres Therapeutics的GAAP每股收益为$0.64,收入为$78万
Seeking Alpha03/13 03:38
Seres Therapeutics | 10-K:年度报表
美股SEC公告03/12 22:01 · 业绩公告
Seres Therapeutics: 第四季度收益简报
Yahoo Finance03/12 19:23